
FIREBRICK PHARMA LIMITED

ACN 157 765 896

NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the Meeting will be held at:

TIME: 11.00am (AEDT)
DATE: Wednesday, 11 November 2026
PLACE: by Virtual Meeting Facility

The Company is pleased to provide Shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic, where Shareholders will be able to watch, listen, and vote online.

Details on how to access the virtual Meeting are set out in this Notice.

For the purpose of Section 249RA of the Corporations Act, the place at which the Meeting of the Company is held is taken to be:

Level 14, 333 Collins Street, Melbourne, Victoria.

The business of the Meeting affects your shareholding and your vote is important.

This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 7.00pm (AEDT) on Monday, 9 November 2026.

NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the Annual General Meeting of the Shareholders of Firebrick Pharma Limited (the **Company**) will be held through the Virtual Meeting Facility on Wednesday, 11 November 2026 commencing at 11.00am (AEDT) (the **Meeting**).

Through the Virtual Meeting Facility, Shareholders will be able to participate in the meeting by listening, asking questions and voting on the resolutions. Shareholders are strongly encouraged to cast their vote by proxy prior to the Meeting in accordance with the instructions set out on page 6 of this Notice to ensure their votes are counted. Further information on how to participate and vote during the Meeting via the Virtual Meeting Facility is set out on page 6 of this Notice.

The Explanatory Statement that accompanies this Notice provides additional information on the matters to be considered at the Meeting. The Explanatory Statement and Proxy Form are part of this Notice.

Should circumstances further change between the date of this Notice of Meeting and the proposed time of the Meeting, the Directors will further update Shareholders with the proposed next steps.

BUSINESS OF THE MEETING

AGENDA

1. FINANCIAL STATEMENTS AND REPORTS

To receive and consider the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the directors, the Directors' Report, the Remuneration Report and the auditor's report.

2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT

To consider and, if thought fit, to pass, with or without amendment, the following resolution as a **non-binding ordinary resolution**:

"That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's annual financial report for the financial year ended 30 June 2026."

Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company.

A voting prohibition statement applies to this Resolution. Please see below.

3. RESOLUTION 2 – ELECTION OF DIRECTOR – AL MOGHADDAM

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of clause 10.3 of the Company's Constitution, ASX Listing Rule 14.4 and for all other purposes, Al Moghaddam having been appointed casually as a Director of the Company on 1 March 2026, retires, and being eligible, is elected as a Director of the Company."

4. RESOLUTION 3 – APPROVAL OF 7.1A MANDATE

To consider and, if thought fit, to pass the following resolution as a **special resolution**:

"That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in the Explanatory Statement."

5. RESOLUTION 4 – ISSUE OF DIRECTOR INCENTIVE OPTIONS TO PETER MOLLOY

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

"That, for the purposes of section 208 of the Corporations Act, ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 18,000,000

Director Incentive Options to Peter Molloy (or his nominee), on the terms and conditions set out in the Explanatory Statement.”

A voting prohibition statement and a voting exclusion statement apply to this Resolution.
Please see below.

6. RESOLUTION 5 – ISSUE OF DIRECTOR INCENTIVE OPTIONS TO STEPHEN GOODALL

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 208 of the Corporations Act, ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 18,000,000 Director Incentive Options to Stephen Goodall (or his nominee), on the terms and conditions set out in the Explanatory Statement.”

A voting prohibition statement and a voting exclusion statement apply to this Resolution.
Please see below.

7. RESOLUTION 6 – ISSUE OF DIRECTOR INCENTIVE OPTIONS TO RICK LEGLEITER

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 208 of the Corporations Act, ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 3,000,000 Director Incentive Options to Rick Legleiter (or his nominee), on the terms and conditions set out in the Explanatory Statement.”

A voting prohibition statement and a voting exclusion statement apply to this Resolution.
Please see below.

8. RESOLUTION 7 – ISSUE OF DIRECTOR INCENTIVE OPTIONS TO AL MOGHADDAM

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 208 of the Corporations Act, ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 3,000,000 Director Incentive Options to Al Moghaddam (or his nominee), on the terms and conditions set out in the Explanatory Statement.”

A voting prohibition statement and a voting exclusion statement apply to this Resolution.
Please see below.

9. RESOLUTION 8 – APPROVAL TO ISSUE AWARDS UNDER THE COMPANY’S EMPLOYEE SECURITIES INCENTIVE PLAN

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That for the purposes of ASX Listing Rule 7.2 exception 13(b), and for all other purposes, approval is given for the Company to issue up to a maximum of 20,000,000 Awards under the Company’s Employee Securities Incentive Plan, on the terms and conditions set out in the Explanatory Statement.”

A voting prohibition statement and a voting exclusion statement apply to this Resolution. Please see below.

10. RESOLUTION 9 – APPOINTMENT OF AUDITOR

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 327B(1)(b) of the Corporations Act and for all other purposes, Criterion Audit Pty Ltd, having been nominated by a Shareholder to act as auditor of the Company and having given its consent in writing to act as auditor of the Company, be appointed as the auditor of the Company to hold office from the conclusion of this Meeting until it resigns or is removed from the office of auditor of the Company.”

Dated: 2 September 2026

By order of the Board

S Buckley
Stephen Buckley
Company Secretary

Voting Prohibition Statements

Resolution 1 – Adoption of Remuneration Report	In accordance with sections 250(BD)(2) and 250R of the Corporations Act, a vote on this Resolution must not be cast: a) by, or on behalf of a member of the Key Management Personnel, details of whose remuneration are included in the Remuneration Report or a Closely Related Party of such a member, regardless of the capacity in which the vote is cast; or b) as a proxy by a member of the Key Management Personnel at the date of the Meeting, or their Closely Related Parties. However, a person (the voter) described above may cast a vote on this Resolution if: a) the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or b) the voter is the Chair and the appointment of the Chair as proxy: i. does not specify the way the proxy is to vote on this Resolution; and ii. expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.
Resolution 4 – Issue of Director Incentive Options to Peter Molloy Resolution 5 – Issue of Director Incentive Options to Stephen Goodall Resolution 6 – Issue of Director Incentive Options to Rick Legleiter Resolution 7 – Issue of Director Incentive Options to Al Moghaddam	In accordance with section 224 of the Corporations Act, a vote on each of these Resolutions must not be cast (in any capacity) by or on behalf of a related party of the Company to whom that Resolution would permit a financial benefit to be given, or an associate of such a related party (Resolutions 4 to 7 Excluded Party). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolutions 4 to 7 Excluded Party. A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.
Resolution 8 – Approval to Issue Awards under the Company’s Employee Securities Incentive Plan	A person appointed as a proxy must not vote on the basis of that appointment, on this Resolution if: a) the Proxy is either: i. a member of the Key Management Personnel; or ii. a Closely Related Party of such a member; and b) the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: a) the proxy is the Chair; b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.

Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the resolution set out below by or on behalf of the following persons:

Resolution 4 – Issue of Director Incentive Options to Peter Molloy	Peter Molloy (or his nominee) and any other person(s) who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Peter Molloy (or his nominee) or those persons.
Resolution 5 – Issue of Director Incentive Options to Stephen Goodall	Stephen Goodall (or his nominee) and any other person(s) who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Stephen Goodall (or his nominee) or those persons.
Resolution 6 – Issue of Director Incentive Options to Rick Legleiter	Rick Legleiter (or his nominee) and any other person(s) who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Rick Legleiter (or his nominee) or those persons.
Resolution 7 – Issue of Director Incentive Options to Al Moghaddam	Al Moghaddam (or his nominee) and any other person(s) who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Al Moghaddam (or his nominee) or those persons.
Resolution 8 – Approval to Issue Awards under the Company’s Employee Securities Incentive Plan	Any person who is eligible to participate in the Employee Securities Incentive Plan or an associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - (ii) the holder votes on the Resolution in accordance with the directions given by the beneficiary to the holder to vote in that way.

How to vote and ask questions

The Company has decided to hold the Meeting as a virtual meeting. You may vote by proxy, personal representative or via the Virtual Meeting Facility.

Shareholders will be able to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business at the conclusion of the Meeting.

Shareholders are also encouraged to submit questions in advance of the Meeting to the Company. Questions must be submitted in writing to the Company Secretary at cosec@firebrickpharma.com at least 48 hours before the Meeting.

Voting by proxy

The Company intends to conduct the Meeting virtually via Automic's platform. Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chair as early as possible and in any event prior to the cut-off for proxy voting as set out in the Notice. Proxy forms can be lodged as below:

- By following the directions on the Proxy Form;
- By scan and email to meetings@automicgroup.com.au;
- In person at Automic, Level 5, 126 Phillip Street, Sydney NSW 2000;
- By post to Automic, GPO Box 5193, Sydney NSW 2001; or
- By facsimile to +61 (0)2 8583 3040.

All proxy forms must be received by the Company not later than **11.00am (AEDT) on Monday, 9 November 2026**.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast 2 or more votes may appoint 2 proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the member appoints 2 proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

In addition:

- if a proxy is given by a body corporate, a Proxy Form must be executed in writing under the common seal of the corporation or otherwise in accordance with section 127 of the Corporations Act or signed by an attorney;
- if a proxy is given by a natural person, a Proxy Form must be executed under the hand of that person or that person's attorney;
- to be effective, the Proxy Form and the power of attorney or other authority (if any) under which it is signed or a certified copy, must be received by the Company at least 48 hours before the time for holding the Meeting or any adjourned Meeting;
- if a Shareholder appoints the Chair as the Shareholder's proxy and does not specify how the Chair is to vote, the Chair will vote, as proxy for that Shareholder, in favour of or against each resolution as set out in the Explanatory Statement;
- a Shareholder that is a body corporate may appoint an individual as its representative to exercise all or any of the powers the body corporate may exercise at the Meeting (the appointment may be a standing one); and
- any Proxy Form received after this deadline will be treated as invalid.

Personal Representative

To vote by personal representative, please forward the authority under which the personal representative has been appointed (or a certified copy of the authority) to the address set out above for the return of Proxy Forms so that it is received no later than **11.00am (AEDT) on Monday, 9 November 2026**.

Corporate Representative

Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company's representative. The authority may be sent to the Company and/or Share Registry in advance of the Meeting. An appointment of corporate representative form can be obtained by via the Company's share registry website – www.automicgroup.com.au.

Preparing to attend the Virtual Meeting

The company is pleased to provide shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic. Shareholders that have an existing account with Automic will be able to watch, listen and vote online.

Shareholders who do not have an account with Automic are strongly encouraged to register for an account **as soon as possible and well in advance of the Meeting** to avoid any delays on the day of the Meeting.

An account can be created via the following link investor.automic.com.au and then clicking on “**Register**” and following the prompts. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.

Attending and Voting at the Virtual Meeting

Shareholders who wish to vote virtually on the day of the AGM can do so by logging in to the Automic shareholder portal:

1. Open your internet browser and go to investor.automic.com.au
2. Login using your username and password. If you do not already have an account, click “**Register**” and follow the prompts. **Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform.**
3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click “**Register**”. Alternatively, select Meetings from the left-hand menu.
4. Click on “**Join Meeting**” and follow the prompts.
5. When the Chair of the Meeting declares the poll open, select the “**Voting**” dropdown menu on the right-hand side of your screen.
6. Select either the “**Full**” or “**Allocate**” option to access your electronic voting card.
7. Follow the prompts to record your voting direction for each resolution and click “**Submit votes**”. For allocated votes, the number of votes submitted must not exceed your remaining available units.

Important: *Votes cannot be amended once submitted.*

For further information on the live voting process please see the **Registration and Voting Guide** at <https://www.automicgroup.com.au/virtual-agms/>

The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business.

Please note that if you have previously submitted a Proxy Form, your online attendance at the Meeting will revoke your proxy's authority to vote, unless you inform the Company otherwise prior to commencement of the Meeting, in which case, your authority to vote at the Meeting is suspended while your proxy is present.

Should you wish to discuss the matters in this Notice of Meeting please do not hesitate to contact the Company Secretary on 1300 301 874.

EXPLANATORY STATEMENT

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

Shareholders should read this statement and the Notice in full before deciding how to vote on the Resolutions set out in the Notice. All Resolutions to be considered at the Meeting will be decided by poll based on both proxy votes received prior to the commencement of the Meeting and votes cast in person at the physical venue or via the online voting facility during the Meeting. Shareholders are encouraged to cast their vote by proxy prior to the Meeting in accordance with the instructions set out on page 6 of this Notice.

1. FINANCIAL STATEMENTS AND REPORTS

In accordance with the Company's Constitution, the business of the Meeting will include receipt and consideration of the annual financial report of the Company for the financial year ended 30 June 2026, together with the declaration of the Directors, the Directors' Report, the Remuneration Report and the auditor's report.

There is no requirement for Shareholders to vote on these statements and reports. Shareholders will be given a reasonable opportunity to raise questions and make comments on these reports and on the management of the Company at the Meeting.

Representatives of the Company's auditor will be present for discussion purposes on matters of relevance to the audit. Written questions to the Company's auditor about:

- (a) the conduct of the audit;
- (b) the preparation and content of the auditor's report;
- (c) accounting policies by the Company in relation to the preparation of the financial statements; and
- (d) the independence of the auditor in relation to the conduct of the audit,

may be submitted no later than 5 Business Days before the Meeting to the Company Secretary at the Company's registered office.

The Company will not provide a hard copy of the Company's annual financial report to Shareholders unless specifically requested to do so. The Company's annual financial report is available on its website at <https://www.firebrickpharma.com/investors/>

2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT

Section 250R(2) of the Corporations Act requires that at a listed company's annual general meeting, a resolution that the company's remuneration report be adopted must be put to the shareholders. However, section 250R(3) of the Corporations Act provides that such a resolution is advisory only and does not bind the company or the directors of the company.

The remuneration report sets out a company's remuneration arrangements for its directors and senior management. The remuneration report is part of the directors' report contained in the annual financial report of a company for a financial year.

The Chair of the meeting must allow a reasonable opportunity for shareholders to ask questions about or make comments on the remuneration report at the annual general meeting.

A company is required to put to its shareholders a resolution proposing the calling of another meeting of shareholders to consider the appointment of directors of the company (**Spill Resolution**) if, at consecutive annual general meetings, at least 25% of the votes cast on a remuneration report resolution are voted against adoption of the remuneration report and at the first of those annual general meetings a Spill Resolution was not put to vote. If required, the Spill Resolution must be put to vote at the second of those annual general meetings.

If more than 50% of votes cast are in favour of the Spill Resolution, the company must convene a shareholder meeting (**Spill Meeting**) within 90 days of the second annual general meeting.

All of the Directors of the Company who were in office when the Directors' Report (as included in the Company's annual financial report for the most recent financial year) was approved, other than the Managing Director of the Company, will cease to hold office immediately before the end of the Spill Meeting but may stand for re-election at the Spill Meeting.

Following the Spill Meeting, those persons whose election or re-election as Directors of the Company is approved will be the Directors of the Company.

At the Company's previous annual general meeting the votes cast against the Remuneration Report considered at that annual general meeting were less than 25%. Accordingly, a Spill Resolution is not relevant for this Annual General Meeting.

2.1 Directors' Recommendation

The Board recommends that Shareholders vote in favour of Resolution 1. The Board encourages Shareholders to apply the same level of diligence to voting on this Resolution as for the binding Resolutions. The Chair of the Meeting intends to vote all available proxies in favour of this Resolution 1.

3. RESOLUTION 2 –ELECTION OF DIRECTOR – AL MOGHADDAM

3.1 General

The Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution.

Pursuant to clause 10.3 of the Company's Constitution and ASX Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders but shall not be taken into account in determining the Directors who are to retire by rotation (if any) at that meeting. If the appointment is not confirmed, the person ceases to be a director at the conclusion of the annual general meeting. Al Moghaddam, having been appointed as a director under clause 10.2(b) by other Directors on 1 March 2026 in accordance with the Company's Constitution, will retire in accordance with clause 10.3(a) of the Company's Constitution and ASX Listing Rule 14.4 and being eligible, seeks election from Shareholders.

3.2 Election of Al Moghaddam

(a) Qualifications and other material directorships

Mr Moghaddam brings three decades of experience across the global Pharma and Healthcare sectors, beginning his career with foundational commercial and leadership roles at Allergan Bristol Myers Squibb and Teva. Over the course of his career, Mr Moghaddam has built a reputation for scaling businesses, commercialising technology globally, leading organisational turnarounds, and dealing with regulators, investors, distribution partners, and payers. His expertise in the US includes managing distribution through wholesale networks, such as McKesson, Cardinal Health and Amerisource, to retail pharmacy partnerships through major US chains such as CVS and Walgreens.

His most recent role was as Global General Manager for Consumer Health at Masimo, where he led the transformation of hospital-grade technology into consumer-ready, over-the-counter medical devices. He oversaw product launches in the US, Canada, UK, Switzerland, and the MENA (Middle East & North Africa) region. Before joining Masimo, Mr Moghaddam founded and led a specialty pharmaceutical startup, which he grew from inception to \$100 million in revenue within five years. He successfully took the company public on both the TSX (Toronto Stock Exchange) and NASDAQ.

Mr Moghaddam brings significant strategic governance and board oversight experience through serving on both NASDAQ and TSX listed company boards. His board committee experience spans audit, compensation and governance, under frameworks similar to the ASX.

(b) Term of office

Al Moghaddam has served as a Director since 1 March 2026.

(c) Independence

If elected, the Board considers that Al Moghaddam will be an independent director within the Company.

(d) **Other material information**

The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person's experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Al Moghaddam. Nothing was revealed by these checks that the Company considers material to a decision by Shareholders on whether or not to elect Al Moghaddam as a Director.

3.3 Technical information required by Listing Rule 14.1A

If Resolution 2 is passed, Al Moghaddam will be elected to the Board as a Non-Executive Director.

In the event that Resolution 2 is not passed, Al Moghaddam will not continue on the Board as a Non-Executive Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company's ability to execute on its strategic vision.

3.4 Directors' Recommendation

Having received an acknowledgement from Al Moghaddam that he will have sufficient time to fulfil his responsibilities as a Director and having reviewed the performance of Al Moghaddam since his appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Al Moghaddam) support the election of Al Moghaddam and recommend that Shareholders vote in favour of this Resolution 2.

The Chair of the meeting intends to vote undirected proxies in favour of this Resolution 2.

4. RESOLUTION 3 – APPROVAL OF 7.1A MANDATE

4.1 General

ASX Listing Rule 7.1A provides that an Eligible Entity may seek shareholder approval by special resolution passed at an annual general meeting to have the capacity to issue up to that number of Equity Securities equal to 10% of its issued capital (**10% Placement Capacity**) without using that company's existing 15% annual placement capacity granted under ASX Listing Rule 7.1.

Broadly speaking, and subject to a number of exceptions, ASX Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without approval of its shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

Under ASX Listing Rule 7.1A, however, an Eligible Entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%.

An 'Eligible Entity' means an entity which is not included in the S&P/ASX 300 Index and which has a market capitalisation of \$300 million or less. The Company is not included in the S&P/ASX 300 index and has a market capitalisation of \$300 million or less and is therefore an Eligible Entity for these purposes. The Company's market capitalisation as at 31 August 2026 is \$10.05 million.

This Resolution 3 seeks shareholder approval by way of special resolution for the Company to have the additional 10% capacity provided for in ASX Listing Rule 7.1A to issue Equity Securities up to the combined 25% limit in ASX Listing Rules 7.1 and 7.1A without any further shareholder approval.

4.2 Technical information required by ASX Listing Rule 14.1A

If this Resolution 3 is passed, the Company will be able to issue equity securities up to the combined 25% limit in ASX Listing Rules 7.1 and 7.1A without any further shareholder approval.

If Resolution 3 is not passed, the Company will not be able to access the additional 10% capacity to issue equity securities without shareholder approval provided for in ASX Listing

Rule 7.1A and will remain subject to the 15% limit on issuing equity securities without shareholder approval set out in ASX Listing Rule 7.1.

This Resolution 3 is a special resolution. Accordingly, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be in favour of Resolution 3 for it to be passed.

4.3 Technical information required by ASX Listing Rule 7.3A

Pursuant to and in accordance with ASX Listing Rule 7.3A, the information below is provided in relation to this Resolution 3:

(a) Date of Issue

The Equity Securities may be issued under the 10% Placement Capacity commencing on the date of the Meeting and expiring on the first to occur of the following:

- (i) 12 months after the date of this Meeting;
- (ii) the time and date of the Company's next Annual General Meeting; and
- (iii) the time and date of approval by Shareholders of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking),

(10% Placement Capacity Period).

(b) Minimum Price

Any Equity Securities issued under the 10% Placement Capacity must be in an existing quoted class of Equity Securities and be issued for cash consideration at a minimum price of 75% of the volume weighted average price of Equity Securities in that class, calculated over the 15 ASX trading days on which trades in that class were recorded immediately before:

- (i) the date on which the price at which the Equity Securities are to be issued is agreed by the Company and the recipient of the Equity Securities; or
- (ii) if the Equity Securities are not issued within 10 trading days of the date in the section 4.3(b)(i) of this Notice, the date on which the Equity Securities are issued.

(c) Purpose of Issue under 10% Placement Capacity

The Company may issue Equity Securities under the 10% Placement Capacity for cash consideration in which case if undertaken, the Company intends to use funds raised to support the Company's growth strategies and general working capital.

(d) Risk of voting dilution

Any issue of Equity Securities under the 10% Placement Capacity will dilute the interests of Shareholders who do not receive any Shares under the issue.

If Resolution 3 is approved by Shareholders and the Company issues the maximum number of Equity Securities available under the 10% Placement Capacity, the economic and voting dilution of existing Shares would be as shown in the table below.

The table below shows the dilution of existing Shareholders calculated in accordance with the formula outlined in ASX Listing Rule 7.1A(2), on the basis of the market price of Shares and the number of Equity Securities on issue as at 31 August 2026.

The table below also shows the voting dilution impact where the number of Shares on issue (Variable A in the formula) changes and the economic dilution where there are changes in the issue price of Shares issued under the 10% Placement Capacity.

Number of Shares on issue (Variable 'A' in ASX Listing Rule 7.1A2)	Potential Dilution and Funds Raised			
	Issue Price (per Share)	\$0.0175 (50% decrease in Issue Price)	\$0.035 (Issue Price)	\$0.07 (100% increase in Issue Price)
Variable A 287,198,985	Shares issued – 10% voting dilution	28,719,898	28,719,898	28,719,898
	Funds raised	\$502,598	\$1,005,196	\$2,010,392
(50% increase in Variable A) 430,798,477	Shares issued – 10% voting dilution	43,079,847	43,079,847	43,079,847
	Funds raised	\$753,897	\$1,507,794	\$3,015,589
(100% increase in Variable A) 574,397,970	Shares issued – 10% voting dilution	57,439,797	57,439,797	57,439,797
	Funds raised	\$1,005,196	\$2,010,392	\$4,020,785

*The number of Shares on issue (Variable A in the formula) could increase as a result of the issue of Shares that do not require Shareholder approval (such as under a pro-rata rights issue or scrip issued under a takeover offer) or that are issued with Shareholder approval under Listing Rule 7.1.

The table above uses the following assumptions:

1. There are 287,198,985 Shares on issue as at the date of this Notice which have either been issued under an exception in Listing Rule 7.2 or with approval under Listing Rule 7.1;
2. The issue price set out above is the closing market price of the Shares on the ASX on 31 August 2026 (being \$0.035).
3. The Company issues the maximum possible number of Equity Securities under the 7.1A Mandate.
4. The issue of Equity Securities under the 7.1A Mandate consists only of Shares. It is assumed that no Options are exercised into Shares before the date of issue of the Equity Securities. If the issue of Equity Securities includes quoted Options, it is assumed that those quoted Options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.
5. The calculations above do not show the dilution that any one particular Shareholder will be subject to. All Shareholders should consider the dilution caused to their own shareholding depending on their specific circumstances.
6. This table does not set out any dilution pursuant to approvals under Listing Rule 7.1 unless otherwise disclosed.
7. The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
8. The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 7.1A Mandate, based on that Shareholder's holding at the date of the Meeting.

Shareholders should note that there is a risk that:

- (i) the market price for the Company's Shares may be significantly lower on the issue date than on the date of the approval under Listing Rule 7.1A; and
- (ii) the Shares may be issued at a price that is at a discount to the market price for those Shares on the date of issue.

(e) **Allocation policy under the 10% Placement Capacity**

The recipients of the Equity Securities to be issued under the 10% Placement Capacity have not yet been determined. However, the recipients of Equity Securities could consist of current Shareholders or new investors (or both), none of whom will be related parties of the Company.

The Company will determine the recipients at the time of the issue under the 10% Placement Capacity, having regard to the following factors:

- (i) the purpose of the issue;
- (ii) alternative methods for raising funds available to the Company at that time, including, but not limited to, an entitlement issue or other offer where existing Shareholders may participate;
- (iii) the effect of the issue of the Equity Securities on the control of the Company;
- (iv) the circumstances of the Company, including, but not limited to, the financial position and solvency of the Company;
- (v) prevailing market conditions; and
- (vi) advice from corporate, financial and broking advisers (if applicable).

Furthermore, if the Company is successful in acquiring new resources, assets or investments, it is likely that the recipients under the 10% Placement Capacity will be vendors of the new resources, assets or investments.

(f) **Equity Securities under ASX Listing Rule 7.1A.2**

The Company obtained approval from its Shareholders pursuant to ASX Listing Rule 7.1A at its Annual General Meeting held on 26 November 2025 (**Previous Approval**).

During the 12-month period preceding the date of the Meeting, being on and from 11 November 2025, the Company issued 25,037,136 Shares pursuant to the Previous Approval (**Previous Issue**), which represents approximately 8.84% of the total diluted number of Equity Securities on issue in the Company on 11 November 2025, which was 283,200,100.

Further details of the issues of Equity Securities by the Company pursuant to Listing Rule 7.1A.2 during the 12-month period preceding the date of the Meeting are set out below.

The following information is provided in accordance with Listing Rule 7.3A.6(b) in respect of the Previous Issue:

Date of Issue and Appendix 2A	Date of Issue and Appendix 2A: 13 April 2026
Recipients	The Shares were issued to participants in the Company's placement announced on 31 March 2026 (Placement), who were either identified through a bookbuild process, which involved SP Corporate Advisory Pty Ltd as lead manager seeking expressions of interest to participate in the capital raising from non-related parties of the Company, or were existing shareholders in the Company. For the purposes of paragraph 7.4 of ASX Guidance Note 21, the Company notes that neither a related party of the Company, nor any member of the Company's Key Management Personnel, substantial holder in the Company, or adviser to the Company, or any associate of any of these, has taken up more

	than 1% of the Company's issued capital at the time of the Placement.
Number and Class of Equity Securities Issued	21,276,603 Shares ²
Issue Price and discount to Market Price¹ (if any)	\$0.047 (4.7 cents) per Share, being a discount of 16.52% to the 15-day VWAP to 26 March 2026 (\$0.0563) and a 22.95% discount to the Market Price, being \$0.061 (6.1 cents).
Total Cash Consideration and Use of Funds	Amount raised: \$1,000,000 Use of funds³: The purpose of the issue was to raise funds intended to be applied to: Costs associated with expansion of Business Development & Licensing (BD&L); New product development (NPD) costs of two new products; Working Capital up to 12 months. Amount spent: \$100,000

Date of Issue and Appendix 2A	Date of Issue and Appendix 2A: 17 April 2026
Recipients	The Shares were issued to participants in the Placement, who were either identified through a bookbuild process, which involved SP Corporate Advisory Pty Ltd as lead manager seeking expressions of interest to participate in the capital raising from non-related parties of the Company, or were existing shareholders in the Company. For the purposes of paragraph 7.4 of ASX Guidance Note 21, the Company notes that neither a related party of the Company, nor any member of the Company's key management personnel, substantial holder in the Company, or adviser to the Company, or any associate of any of these, has taken up more than 1% of the Company's issued capital at the time of the Placement.
Number and Class of Equity Securities Issued	3,760,533 Shares ²
Issue Price and discount to Market Price¹ (if any)	\$0.047 (4.7 cents) per Share, being a discount of 16.52% to the 15-day VWAP to 26 March 2026 (\$0.0563) and a 25.40% discount to the Market Price, being \$0.063 (6.3 cents).
Total Cash Consideration and Use of Funds	Amount raised: \$176,745 Use of funds³: The purpose of the issue was to raise funds intended to be applied to: Costs associated with expansion of Business Development & Licensing (BD&L); New product development (NPD) costs of two new products; Working Capital up to 12 months. Amount spent: Nil

Notes:

1. Market Price means the closing price of Shares on ASX (excluding special crossings, overnight sales and exchange traded option exercises). For the purposes of this table the discount is calculated on the Market Price on the last trading day on which a sale was recorded prior to the date of issue of the relevant Equity Securities.
2. Fully paid ordinary shares in the capital of the Company, ASX Code: FRE (terms are set out in the Constitution).
3. This is a statement of current intentions as at the date of this Notice. As with any budget, intervening events and new circumstances have the potential to affect the manner in which the funds are ultimately applied. The Board reserves the right to alter the way the funds are applied on this basis.

(g) **Compliance with ASX Listing Rules 7.1A.4 and 3.10.3**

When the Company issues Equity Securities pursuant to the 10% Placement Capacity, it must:

- (i) state in its announcement of the proposed issue under ASX Listing Rule 3.10.3 or in its application for quotation of the securities under ASX Listing Rule 2.7 that the securities are being issued under ASX Listing Rule 7.1A; and
- (ii) give to ASX immediately after the issue a list of names of the persons to whom the entity issued the equity securities and the number of equity securities issued to each. This list is not for release to the market.

The Company will comply with the disclosure obligations under ASX Listing Rules 7.1A.4 and 3.10.3 upon issue of any Equity Securities.

4.4 Voting Exclusion

As at the date of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing Rule 7.1A. Accordingly, a voting exclusion statement is not included in this Notice.

4.5 Directors Recommendation

The Directors consider the approval of the 10% Placement Capacity to be in the best interests of the Company and recommend that Shareholders vote in favour of Resolution 3 to give effect to the approval.

The Chair of the meeting intends to vote undirected proxies in favour of Resolution 3.

5. RESOLUTIONS 4 TO 7 – ISSUE OF DIRECTOR INCENTIVE OPTIONS TO DIRECTORS, PETER MOLLOY, STEPHEN GOODALL, RICK LEGLEITER AND AL MOGHADDAM

5.1 General

Resolutions 4 to 7 seek shareholder approval for the proposed issue of an aggregate of 42,000,000 unlisted Options on the terms and conditions set out in Schedule 1 (**Director Incentive Options**) to Peter Molloy, Stephen Goodall, Rick Legleiter and Al Moghaddam, the Directors of the Company, (or their nominee/s) on the terms and conditions set out below.

It is proposed that the Directors will receive the following Director Incentive Options:

- (a) 18,000,000 unlisted Director Incentive Options on the terms and conditions outlined in Schedule 1 to Peter Molloy (or his nominee/s), subject to Shareholder approval pursuant to Resolution 4;
- (b) 18,000,000 unlisted Director Incentive Options on the terms and conditions outlined in Schedule 1 to Stephen Goodall (or his nominee/s), subject to Shareholder approval pursuant to Resolution 5;
- (c) 3,000,000 unlisted Director Incentive Options on the terms and conditions outlined in Schedule 1 to Rick Legleiter (or his nominee/s), subject to Shareholder approval pursuant to Resolution 6; and
- (d) 3,000,000 unlisted Director Incentive Options on the terms and conditions outlined in Schedule 1 to Al Moghaddam (or his nominee/s), subject to Shareholder approval pursuant to Resolution 7.

5.2 Director Recommendation

Each of the Directors have a material personal interest in the outcome of Resolutions 4 to 7 on the basis that all of the Directors (or their nominee(s)) are to be issued Director Incentive Options should Resolutions 4 to 7 be passed. For this reason, the Directors abstain from making a recommendation in relation to Resolutions 4 to 7.

The Chair of the meeting intends to vote undirected proxies in favour of these Resolutions 4 to 7.

5.3 Chapter 2E of the Corporations Act

For a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue of Director Incentive Options to the Directors constitutes giving a financial benefit and each of the Directors is a related party of the Company by virtue of being a Director.

As the Director Incentive Options are proposed to be issued to all of the Directors, the Directors are unable to form a quorum to consider whether one of the exceptions set out in sections 210 to 216 of the Corporations Act applies to the issue of the Director Incentive Options. Accordingly, Shareholder approval for the issue of Director Incentive Options to the Directors is sought in accordance with Chapter 2E of the Corporations Act.

5.4 Listing Rule 10.11

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to:

- 10.11.1 a related party;
- 10.11.2 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the company;
- 10.11.3 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;
- 10.11.4 an associate of a person referred to in ASX Listing Rules 10.11.1 to 10.11.3; or
- 10.11.5 a person whose relationship with the company or a person referred to in ASX Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The issue of Director Incentive Options falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

Resolutions 4 to 7 seek the required Shareholder approval for the issue of the Director Incentive Options under and for the purposes of Listing Rule 10.11.

5.5 Technical Information required by Listing Rule 14.1A

If Resolutions 4 to 7 are passed, the Company will be able to proceed with the issue of the Director Incentive Options within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the ASX Listing Rules). As approval pursuant to Listing Rule 7.1 is not required for the issue of the Director Incentive Options (because approval is being obtained under Listing Rule 10.11 which falls under Listing Rule 7.2 Exception 14), the issue of the Director Incentive Options will not use up any of the Company's 15% annual placement capacity.

If Resolutions 4 to 7 are not passed, the Company will not be able to proceed with the issue of the Director Incentive Options.

5.6 Technical information required by Listing Rule 10.13 and section 219 of the Corporations Act

Pursuant to and in accordance with Listing Rule 10.13 and section 219 of the Corporations Act, the following information is provided in relation to Resolutions 4 to 7:

- (a) the Director Incentive Options will be issued to Peter Molloy, Stephen Goodall, Rick Legleiter and Al Moghaddam (or their nominees), who each fall within the category set out in Listing Rule 10.11.1 as each are a related party of the Company by virtue of being a Director;
- (b) any nominee(s) of the proposed recipients who receive Securities may constitute 'associates' for the purposes of Listing Rule 10.11.4;
- (c) the maximum number of Director Incentive Options to be issued (being the nature of the financial benefit proposed to be given) is 42,000,000 and will be allocated as follows:
 - (i) 18,000,000 Director Incentive Options to be issued to Peter Molloy (or his nominee/s);
 - (ii) 18,000,000 Director Incentive Options to be issued to Stephen Goodall (or his nominee/s);
 - (iii) 3,000,000 Director Incentive Options to be issued to Rick Legleiter (or his nominee/s); and
 - (iv) 3,000,000 Director Incentive Options to be issued to Al Moghaddam (or his nominee/s);
- (d) the terms and conditions of the Director Incentive Options are set out in Schedule 1;
- (e) the Director Incentive Options will be issued no later than 1 month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the ASX Listing Rules);
- (f) the issue price of the Director Incentive Options will be nil. The Company will not receive any other consideration in respect of the issue of the Director Incentive Options (other than in respect of funds received on exercise of the Director Incentive Options);
- (g) the main purpose of the issue of the Director Incentive Options is to provide a retention incentive component in the remuneration package for the Directors to align the interests of the Directors with those of Shareholders, to motivate and reward the long-term performance of the Directors in their roles and to provide a cost effective way from the Company to remunerate the Directors, which will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to the proposed recipients;
- (h) the Director Incentive Options are unquoted Director Incentive Options. The Company has agreed to issue the Director Incentive Options to the Directors subject to Shareholder approval pursuant to Resolutions 4 to 7 for the following reasons:
 - (i) the Director Incentive Options are unquoted; therefore, the issue of the Director Incentive Options has no immediate dilutionary impact on Shareholders;
 - (ii) the deferred taxation benefit available to the Directors on an issue of Director Incentive Options is also beneficial to the Company, as it means the Directors are not required to immediately sell the Director Incentive Options to fund a tax liability (as would be the case with an issue of Shares, where the liability arises on issue) and will instead continue to hold an interest in the Company;
 - (iii) the issue is a reasonable and appropriate method of providing cost-effective remuneration, as the non-cash form of the benefit allows the Company to spend a greater proportion of its cash reserves on its operations than if alternative cash forms of remuneration were provided to the Directors; and

- (iv) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Director Incentive Options on the terms proposed;
- (i) the number of Director Incentive Options to be issued to each of the Directors has been determined based upon a consideration of:
 - (i) current market standards and/or practices of other ASX listed companies of a similar size and stage of development to the Company;
 - (ii) the remuneration of the Directors; and
 - (iii) incentives to attract and ensure continuity of service of the Directors who have appropriate knowledge and expertise, while maintaining the Company's cash reserves;
- (j) the current total remuneration package for Peter Molloy is \$378,110 per annum plus statutory superannuation, comprising of directors' fees/salary, together with additional reimbursement benefits. The Director Incentive Options (which have been valued as per Schedule 2) have an estimated total value of \$558,318;
- (k) the current total remuneration package for Stephen Goodall is \$308,528 per annum plus statutory superannuation, comprising of directors' fees/salary, together with additional reimbursement benefits. The Director Incentive Options (which have been valued as per Schedule 2) have an estimated total value of \$558,318;
- (l) the current total remuneration package for Rick Legleiter is \$60,000 per annum, comprising of directors' fees/salary, together with additional reimbursement benefits. The Director Incentive Options (which have been valued as per Schedule 2) have an estimated total value of \$93,053;
- (m) the current total remuneration package for Al Moghaddam is \$72,000 per annum comprising of directors' fees/salary, together with additional reimbursement benefits. The Director Incentive Options (which have been valued as per Schedule 2) have an estimated total value of \$93,053;
- (n) the relevant interests of the Directors in securities of the Company as at the date of this Notice, excluding any interests in the Director Incentive Options contemplated by this Notice, are set out below:

As at the date of this Notice

Director	Shares ¹	Options	Undiluted ²	Fully Diluted
Peter Molloy	32,056,017	-	11.16%	9.59%
Stephen Goodall	31,148,290	-	10.85%	9.31%
Rick Legleiter	-	1,000,000 ³	-	0.30%
Al Moghaddam	-	1,000,000 ⁴	-	0.30%

Post-issue of the Director Incentive Options to Directors

Director	Shares ¹	Options
Peter Molloy	32,056,017	18,000,000 ⁵
Stephen Goodall	31,148,290	18,000,000 ⁵
Rick Legleiter	-	1,000,000 ³ 3,000,000 ⁵
Al Moghaddam	-	1,000,000 ⁴ 3,000,000 ⁵

Notes:

1. Fully paid ordinary shares in the capital of the Company (ASX: FRE).
2. Based on 287,198,985 Shares on issue as at the date of this Notice.
3. Unquoted Options exercisable at \$0.15 each on or before 1 August 2029.
4. Unquoted Options exercisable at \$0.15 each on or before 10 February 2030.
5. Unquoted Options exercisable on the terms and conditions set out in Schedule 1.

- (o) if the Director Incentive Options issued to the Directors are exercised, a total of 42,000,000 Shares would be issued. This will increase the number of Shares on issue from 287,198,985 to 329,198,985 (assuming that no Shares are issued and no existing convertible securities vest or are exercised) with the effect that the shareholding of existing Shareholders would be diluted by an aggregate of 9.95%, comprising 4.05% by Peter Molloy, 4.08% by Stephen Goodall, 0.91% by Rick Legleiter and 0.91% by Al Moghaddam.

The market price for Shares during the term of the Director Incentive Options would normally determine whether the Director Incentive Options are exercised. If, at any time any of the Director Incentive Options are exercised and the Shares are trading on ASX at a price that is higher than the exercise price of the Director Incentive Options, there may be a perceived cost to the Company.

- (p) the trading history of the Shares on ASX in the 12 months before the date of this Notice are set out below:

	Price	Date
Highest	\$0.081	5 August 2025 & 18 August 2025
Lowest	\$0.024	3 – 4 August 2026
Last	\$0.035	31 August 2026

- (q) the Board is not aware of any other information that is reasonably required by Shareholders to allow them to decide whether it is in the best interests of the Company to pass Resolutions 4 to 7;

- (r) a voting exclusion statement is included for Resolutions 4 to 7 of this Notice of Meeting; and
- (s) a voting prohibition statement is included for Resolutions 4 to 7 of this Notice of Meeting.

6. RESOLUTION 8 – APPROVAL TO ISSUE AWARDS UNDER THE COMPANY'S EMPLOYEE SECURITIES INCENTIVE PLAN

6.1 General

The Company has adopted an employee incentive plan called the “Firebrick Pharma Employee Securities Incentive Plan” (**Plan**). The Plan provides an opportunity to eligible participants to participate in the Company's future. Further, the Plan acts as a mechanism to ensure the interests of Shareholders, management and employees of the Company are aligned.

Resolution 8 seeks Shareholder approval for the purposes of Listing Rule 7.2 exception 13(b) for the issue of a maximum of 20,000,000 Awards under the Plan. A summary of the Plan is set out in Schedule 3. Further details relating to the Listing Rule requirements, including a renewed maximum number of Awards that may be issued, is set out below in this Section 6.4.

6.2 Listing Rule 7.1

Subject to certain exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without approval of its Shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

Under Listing Rule 7.2, Exception 13(b), an issue of Equity Securities under an employee incentive scheme is excluded from the 15% capacity limit imposed by Listing Rule 7.1 if the issue is made under an employee incentive scheme that was approved by the entity's Shareholders within 3 years before the date of issue.

6.3 Technical Information required by Listing Rule 14.1A

If this Resolution 8 is passed, the Company will be able to issue Securities under the Plan to eligible participants over a period of 3 years which will be treated as having been made with the approval of Shareholders for the purposes of Listing Rule 7.1 and will be excluded from the 15% capacity limit. If Resolution 8 is not passed, any Equity Securities issued under the Plan that exceed the 15% limit in Listing Rule 7.1 will require the approval of Shareholders, unless the issue falls within one of the exceptions in Listing Rule 7.2.

However, any future issues of Equity Securities under the Plan to a related party or a person whose relationship with the Company or the related party is, in ASX's opinion, such that approval should be obtained, will require additional Shareholder approval under Listing Rule 10.14 at the relevant time.

6.4 Information required by ASX Listing Rule 7.2, Exception 13(b)

Pursuant to and in accordance with ASX Listing Rule 7.2, Exception 13(b), the following information is provided in relation to Resolution 8:

- a) a summary of the terms of the Plan is contained in Schedule 3 to this Explanatory Statement;
- b) the Plan was previously approved by Shareholders on 26 November 2025;
- c) a total of 1,000,000 Equity Securities have been issued pursuant to the Plan since it was last approved by Shareholders;
- d) the maximum number of Awards proposed to be issued under the Plan under Exception 13(b) to Listing Rule 7.2 following approval of this Resolution is 20,000,000 Awards;
- e) a voting exclusion statement has been included in the Notice for the purposes of Resolution 8; and
- f) a voting prohibition statement has been included in the Notice for the purposes of Resolution 8.

6.5 Directors' Recommendation

The Directors recommend that Shareholders vote in favour of this Resolution 8.

The Chair of the meeting intends to vote undirected proxies in favour of this Resolution 8.

7. RESOLUTION 9 – APPOINTMENT OF AUDITOR

7.1 General

This Resolution 9 seeks shareholder approval for the appointment of Criterion Audit Pty Ltd to the office of auditor of the Company, having been appointed by the Board to fill the vacancy pursuant to section 327C of the Corporations Act following the resignation of BDO Audit Pty Ltd, effective 1 December 2025 (ASX announcement dated 21 November 2025).

Section 327C(2) notes that an auditor appointed to fill a vacancy holds office until the company's next AGM at which time they must be appointed by shareholders to continue to act as auditor of the Company. This is the Company's first Annual General Meeting after having appointed Criterion Audit Pty Ltd to the position of Auditor.

Section 327B(1)(b) of the Corporations Act also provides that at each annual general meeting, the Company must appoint an auditor to fill any vacancy in the office of auditor. Accordingly, the Company is seeking Shareholder Approval for the appointment of Criterion Audit Pty Ltd as the auditor of the Company and its controlled entities.

The Company has received the consent to appointment from Criterion Audit Pty Ltd in accordance with section 328A of the Corporations Act, along with the resignation as auditor from BDO Audit Pty Ltd, in accordance with section 329(5) of the Corporations Act, which was also lodged with and accepted by the Australian Securities and Investments Commission.

In accordance with section 328B(1) of the Corporations Act, the Company has sought and obtained a nomination from a shareholder for Criterion Audit Pty Ltd to be appointed as the Company's auditor. A copy of this nomination is annexed as Annexure A to this Explanatory Statement.

If Resolution 9 is passed, the appointment of Criterion Audit Pty Ltd will take effect from the close of the Meeting.

7.2 Directors' Recommendation

The Directors recommend that Shareholders vote in favour of this Resolution 9.

The Chair of the meeting intends to vote undirected proxies in favour of this Resolution 9.

8. GLOSSARY

\$ means Australian dollars.

10% Placement Capacity has the meaning given in section 4.1

AEDT means Australian Eastern Daylight Time as observed in Melbourne, Victoria.

Annual General Meeting or **Meeting** means the meeting convened by the Notice.

Associate has the meaning given in the ASX Listing Rules.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

ASX Listing Rules means the Listing Rules of ASX.

Award means a Security that may be issued under the Plan.

Board means the current board of Directors of the Company.

Business Day means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

Chair means the chair of the Meeting.

Closely Related Party has the meaning given in section 9 of the Corporations Act.

Company means Firebrick Pharma Limited (ACN 157 765 896).

Constitution means the Company's constitution.

Corporations Act means the *Corporations Act 2001* (Cth).

Directors means the current directors of the Company.

Director Incentive Options has the meaning given to that term in Section 5.1.

Eligible Entity means an entity that, at the date of the relevant general meeting:

- (a) is not included in the S&P/ASX 300 Index; and
- (b) has a maximum market capitalisation (excluding restricted securities and securities quoted on a deferred settlement basis) of \$300,000,000.

Equity Securities includes a Share, a right to a Share or Option, an Option, a convertible security and any security that ASX decides to classify as an Equity Security.

Explanatory Statement means the explanatory statement accompanying the Notice.

Key Management Personnel has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.

Managing Director means the managing director of the Company who may, in accordance with the ASX Listing Rules, continue to hold office indefinitely without being re-elected to the office.

Notice or **Notice of Meeting** means this notice of meeting including the Explanatory Statement and the Proxy Form.

Option means an option to acquire a Share.

Previous Approval has the meaning given to that term in Section 4.3(f).

Previous Issue has the meaning given to that term in Section 4.3(f).

Proxy Form means the proxy form accompanying the Notice.

Related Body Corporate has the meaning given in section 9 of the Corporations Act.

Remuneration Report means the remuneration report set out in the Directors' Report section of the Company's annual financial report for the year ended 30 June 2026.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Section means a section of the Explanatory Statement.

Security means a Share or Option (as applicable).

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Share Registry means Automic Registry Services.

Variable A means "A" as set out in the formula in ASX Listing Rule 7.1A(2).

Virtual Meeting Facility means the online meeting platform powered by Automic Group.

Volume Weighted Average Price (VWAP) in relation to the ordinary fully paid shares of Firebrick Pharma Limited for a particular period, means the volume weighted average price of trading in the ordinary fully paid shares on the ASX market and the Chi-X market over that period, excluding block trades, large portfolio trades, permitted trades during the pre-trading hours period, permitted trades during the post-trading hours period, out of hours trades and exchange traded option exercises.

SCHEDULE 1: TERMS AND CONDITIONS OF DIRECTOR INCENTIVE OPTIONS

1.	Entitlement	Subject to paragraph 14, each Option entitles the holder to subscribe for one Share upon exercise of the Option.
2.	Exercise Price	Subject to paragraphs 11 and 13, the amount payable upon exercise of each Option will be two times the VWAP of Firebrick Pharma shares (ASX:FRE) for the 20 trading days prior to the date of the Annual General Meeting (Exercise Price).
3.	Expiry Date	Each Option will expire at 5:00 pm (AEDT), five (5) years from the date of issue (Expiry Date). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
4.	Exercise Period	The Options are exercisable at any time on or prior to the Expiry Date (Exercise Period).
5.	Vesting	The Options issued will vest in equal instalments every quarter over the first three years after the date of issue and will be subject to the continued service of the relevant Director at the time of vesting.
6.	Exercise Notice	The Options may be exercised during the Exercise Period by notice in writing to the Company (Notice of Exercise) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company. Any Notice of Exercise of an Option received by the Company will be deemed to be effective notice of the exercise of that Option on and from the date of receipt of the Notice of Exercise and the receipt of the full amount of the Exercise Price for each Option exercised in cleared funds. The Options may only be exercised in multiples of 10,000 on each occasion.
7.	Exercise Date	An Exercise Notice is only effective on and from the later of the date of receipt of the Exercise Notice and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (Exercise Date).
8.	Forfeiture Conditions	Options will be forfeited in the following circumstances: (a) an unauthorised dealing in, or hedging of, the Option occurring; (b) in respect of unvested Options only, a relevant person ceases to be a Director, unless the Board in its absolute discretion, resolves to allow the unvested Options to remain unvested after the relevant person ceases to be a Director; (c) in respect of vested Options only, a relevant person ceases to be a Director and the Option granted in respect of that relevant person is not exercised within one (1) month (or such later date as the Board determines) of the date the relevant person ceases to be a Director; (d) the Board deems that an Option lapses due to fraud, dishonesty or other improper behaviour of the holder; (e) the Company undergoes a change of control or a winding up resolution or order is made, and the Option does not vest in accordance with these terms; and (f) the Expiry Date of the Option.
9.	Timing of issue of Shares on exercise	Within five Business Days after the Exercise Date, the Company will: (a) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in

		the Exercise Notice and for which cleared funds have been received by the Company; (b) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and (c) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options. If a notice delivered under 9(b) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.
10.	Shares issued on exercise	Shares issued on exercise of the Options rank equally with the then issued Shares of the Company.
11.	Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the holder will be varied to comply with the ASX Listing Rules which apply to the reorganisation at the time of the reorganisation.
12.	Participation in new issues	There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options. However, the Company will give holders of the Options notice of the proposed issue prior to the date for determining entitlements to participate in any such issue.
13.	Change in exercise price/Adjustment for rights issue	If the Company makes an issue of Shares pro rata to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment), the Exercise Price of an Option will be adjusted according to the following formula: $\text{New exercise price} = O - \frac{E[P-(S+D)]}{N+1}$ Where: O = the old Exercise Price of the Option. E = the number of underlying Shares into which one Option is exercisable. P = average market price per Share weighted by reference to volume of the Company's Shares during the 5 trading days ending on the day before the ex rights date or ex entitlements date of the relevant pro rata issue. S = the subscription price of a Share under the pro rata issue. D = the dividend due but not yet paid on the existing underlying Shares (except those to be issued under the pro rata issue). N = the number of Shares with rights or entitlements that must be held to receive a right to one Share.
14.	Adjustment for bonus issues of Shares	If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment): (a) the number of Shares or other securities which must be issued on the exercise of an Option will be increased by the

		number of Shares or other securities which the holder would have received if the holder had exercised the Option before the record date for the bonus issue; and (b) no change will be made to the Exercise Price.
15.	Transferability	The Options will not be transferable.

SCHEDULE 2: VALUATION OF DIRECTOR INCENTIVE OPTIONS

The Director Incentive Options, proposed to be issued pursuant to Resolutions 4 to 7 have been valued using the Black & Scholes option valuation methodology and based on the assumptions set out below. The estimated value of the Director Incentive Options is as follows:

Assumptions	
Assumed grant date	1 September 2026
Assumed expiry date	31 August 2031
Share price at assumed grant date	\$0.035
Exercise price	\$0.06
Risk free rate %	4.55%
Volatility %	148%
Dividend yield %	n/a
Fair value per Option	\$0.0310177
Total Value of Options – Peter Molloy (18M)	\$558,318
Total Value of Options – Stephen Goodall (18M)	\$558,318
Total Value of Options – Rick Legleiter (3M)	\$93,053
Total Value of Options – Al Moghaddam (3M)	\$93,053

Note: The indicative valuations noted above are not necessarily the market price that the Director Incentive Options could be traded at and are not necessarily the appropriate values for taxation purposes.

Assumptions:

- in calculating the value of the options, the Black-Scholes model has been used. This is a recognised valuation tool under AASB 2.
- the grant date for this valuation purpose is 1 September 2026.
- the grant date share price as above is taken to be the last trading price available (being price at 31 August 2026).
- the expiry date for this valuation purpose is 31 August 2031.
- the exercise price is two times the VWAP of FRE for the 20 trading days prior to the assumed grant date of 1 Sept 2026. This will change close to the AGM date.
- each option will convert into one (1) fully paid ordinary share in FRE.
- The annualised historical volatility of returns on Firebrick's for the 1-year period to 31 August 2026 based on the daily closing prices of shares traded on ASX was 148%.
- the risk free interest rate is estimated based on the Australian Treasury bond rate over the life of the options (5 year) sources from the Reserve Bank of Australia. Since the August 2026 data is not yet released, we have used the July 2026 data

SCHEDULE 3: EMPLOYEE SECURITIES INCENTIVE PLAN SUMMARY

A summary of the key terms of the Plan is set out below:

- (a) **(Eligible Participant):** Eligible Participant means a person that:
- (i) is an 'ESS participant' (as that term is defined in Division 1A of Part 7.12 of the Corporations Act) in relation to the Company for an invitation made on or after 1 October 2022; and
 - (ii) has been determined by the Board to be eligible to participate in the Plan from time to time.
- (b) **(Purpose):** The purpose of the Plan is to:
- (i) assist in the reward, retention and motivation of Eligible Participants;
 - (ii) link the reward of Eligible Participants to Shareholder value creation; and
 - (iii) align the interests of Eligible Participants with shareholders of the Group (being the Company and each of its Associated Bodies Corporate), by providing an opportunity to Eligible Participants to receive an equity interest in the Company in the form of Securities.
- (c) **(Plan administration):** The Plan will be administered by the Board. The Board may exercise any power or discretion conferred on it by the Plan rules in its sole and absolute discretion except to the extent that it prevents the Company relying on the deferred tax concessions under Subdivision 83A-C of the *Income Tax Assessment Act 1997* (Cth). The Board may delegate its powers and discretion.
- (d) **(Eligibility, invitation and application):** The Board may from time to time determine that an Eligible Participant may participate in the Plan and make an invitation to that Eligible Participant to apply for Securities on such terms and conditions as the Board decides.
- On receipt of an invitation, an Eligible Participant may apply for the Securities the subject of the invitation by sending a completed application form to the Company. The Board may accept an application from an Eligible Participant in whole or in part. If an Eligible Participant is permitted in the invitation, the Eligible Participant may, by notice in writing to the Board, nominate a party in whose favour the Eligible Participant wishes to renounce the invitation.
- (e) **(Grant of Securities):** The Company will, to the extent that it has accepted a duly completed application, grant the Participant the relevant number of Securities, subject to the terms and conditions set out in the invitation, the Plan rules and any ancillary documentation required.
- (f) **(Terms of Convertible Securities):** Each 'Convertible Security' represents a right to acquire one or more Shares (for example, under an option or performance right), subject to the terms and conditions of the Plan.
- Prior to a Convertible Security being exercised a Participant does not have any interest (legal, equitable or otherwise) in any Share the subject of the Convertible Security by virtue of holding the Convertible Security. Unless in 'Special Circumstances' (as defined in the Plan) with the consent of the Board, a Participant may not sell, assign, transfer, grant a security interest over, collateralise a margin loan against, utilise for the purposes of short selling, enter into a Derivative with reference to, or otherwise deal with a Convertible Security that has been granted to them. A Participant must not enter into any arrangement for the purpose of hedging their economic exposure to a Convertible Security that has been granted to them.
- (g) **(Vesting of Convertible Securities):** Any vesting conditions applicable to the grant of Convertible Securities will be described in the invitation. If all the vesting conditions are satisfied and/or otherwise waived by the Board, the Company shall notify the Participant as soon as practicable on or after the vesting, informing them that the relevant Convertible Securities have vested. Unless and until the vesting notice is issued by the Company, the Convertible Securities will not be considered to have vested. For the avoidance of doubt, if the vesting conditions relevant to a Convertible Security are not satisfied and/or otherwise waived by the Board, that Convertible Security will lapse.

- (h) **(Exercise of Convertible Securities and cashless exercise):** To exercise a Convertible Security, the Participant must deliver a signed notice of exercise and, subject to a cashless exercise of Convertible Securities (see below), pay the exercise price (if any) to or as directed by the Company, at any time prior to the earlier of any date specified in the vesting notice and the expiry date as set out in the invitation.

A Convertible Security may not be exercised unless and until that Convertible Security has vested in accordance with the Plan rules, or such earlier date as set out in the Plan rules.

- (i) **(Cashless exercise of Convertible Securities):** At the time of exercise of the Convertible Securities, subject to Board approval at that time, the Participant may elect not to be required to provide payment of the exercise price for the number of Convertible Securities specified in a notice of exercise, but that on exercise of those Convertible Securities the Company will transfer or issue to the Participant that number of Shares equal in value to the positive difference between the Market Value of the Shares at the time of exercise and the exercise price that would otherwise be payable to exercise those Convertible Securities.

Market Value means, at any given date, the volume weighted average price per Share traded on the ASX over the 5 trading days immediately preceding that given date, unless otherwise specified in an invitation.

If the difference between the total exercise price otherwise payable for the Convertible Securities being exercised and the then market Value of the Share at the time of exercise and the exercise price is zero or negative, then the Eligible Participant will not be entitled to use the cashless exercise facility.

- (j) **(Delivery of Shares on exercise of Convertible Securities):** As soon as practicable after the valid exercise of a Convertible Security by a Participant, the Company will issue or cause to be transferred to that Participant the number of Shares to which the Participant is entitled under the Plan rules and issue a substitute certificate for any remaining unexercised Convertible Securities held by that Participant.

- (k) **(Forfeiture of Convertible Securities):** Where a Participant who holds Convertible Securities ceases to be an Eligible Participant or becomes insolvent, all unvested Convertible Securities will automatically be forfeited by the Participant, unless the Board otherwise determines in its discretion to permit some or all of the Convertible Securities to vest.

Where the Board determines that a Participant has acted fraudulently or dishonestly, acted negligently, acted in contravention of a Group policy or wilfully breached his or her duties to the Group, the Board will deem all unvested Convertible Securities held by that Participant to have been forfeited.

Unless the Board otherwise determines, or as otherwise set out in the Plan rules:

- (i) any Convertible Securities which have not yet vested will be forfeited immediately on the date that the Board determines (acting reasonably and in good faith) that any applicable vesting conditions have not been met or cannot be met by the relevant date; and
- (ii) any Convertible Securities which have not yet vested will be automatically forfeited on the expiry date specified in the invitation.
- (l) **(Change of control):** If a change of control event occurs in relation to the Company, or the Board determines that such an event is likely to occur, the Board may in its discretion determine the manner in which any or all of the Participant's Convertible Securities will be dealt with, including, without limitation, in a manner that allows the Participant to participate in and/or benefit from any transaction arising from or in connection with the change of control event.
- (m) **(Rights attaching to Plan Shares):** All Shares issued under the Plan, or issued or transferred to a Participant upon the valid exercise of a Convertible Security, **(Plan Shares)** will rank pari passu in all respects with the Shares of the same class. A Participant will be entitled to any dividends declared and distributed by the Company on the Plan Shares and may participate in any dividend reinvestment plan operated by the Company in respect of Plan Shares. A Participant may exercise any voting rights attaching to Plan Shares.
- (n) **(Disposal restrictions on Plan Shares):** If the invitation provides that any Plan Shares are subject to any restrictions as to the disposal or other dealing by a Participant for a period, the Board may implement any procedure it deems appropriate to ensure the compliance by the

Participant with this restriction.

For so long as a Plan Share is subject to any disposal restrictions under the Plan, the Participant will not:

- (i) transfer, encumber or otherwise dispose of, or have a security interest granted over that Plan Share; or
 - (ii) take any action or permit another person to take any action to remove or circumvent the disposal restrictions without the express written consent of the Company.
- (o) **(Adjustment of Convertible Securities):** If there is a reorganisation of the issued share capital of the Company (including any subdivision, consolidation, reduction, return or cancellation of such issued capital of the Company), the rights of each Participant holding Convertible Securities will be changed to the extent necessary to comply with the Listing Rules applicable to a reorganisation of capital at the time of the reorganisation.

If Shares are issued by the Company by way of bonus issue (other than an issue in lieu of dividends or by way of dividend reinvestment), the holder of Convertible Securities is entitled, upon exercise of the Convertible Securities, to receive an allotment of as many additional Shares as would have been issued to the holder if the holder held Shares equal in number to the Shares in respect of which the Convertible Securities are exercised.

Unless otherwise determined by the Board, a holder of Convertible Securities does not have the right to participate in a pro rata issue of Shares made by the Company or sell renounceable rights.

- (p) **(Participation in new issues):** There are no participation rights or entitlements inherent in the Convertible Securities and holders are not entitled to participate in any new issue of Shares of the Company during the currency of the Convertible Securities without exercising the Convertible Securities.
- (q) **(Compliance with Applicable Laws):** Notwithstanding the Plan rules or any terms of a Security, no Security may be offered, granted, vested or exercised, and no Share may be issued or transferred, if to do so would contravene any applicable laws.

Where monetary consideration is payable by the Eligible Participant, and in respect to Convertible Securities where the Exercise Price on exercise of those Convertible Securities is greater than zero, the Company must reasonably believe when making an invitation:

- (i) the total number of Plan Shares that are, or are covered by the Securities that may be issued under an invitation; and
- (ii) the total number of Plan Shares that are, or are covered by the Securities that have been issued, or could have been issued in connection with the Plan in reliance on Division 1A of Part 7.12 of the Corporations Act at any time during the previous 3 year period prior to the date the invitation is made,

does not exceed:

- (i) if the Constitution specifies an issue cap percentage, that percentage; or
- (ii) if the Constitution does not specify an issue cap percentage, 5% (or such other maximum permitted under any Applicable Law),

of the total number of Shares on issue at the date of the invitation.

- (r) **(Amendment of Plan):** Subject to the following paragraph, the Board may at any time amend any provisions of the Plan rules, including (without limitation) the terms and conditions upon which any Securities have been granted under the Plan and determine that any amendments to the Plan rules be given retrospective effect, immediate effect or future effect.

No amendment to any provision of the Plan rules may be made if the amendment materially reduces the rights of any Participant as they existed before the date of the amendment, other than an amendment introduced primarily for the purpose of complying with legislation or to correct manifest error or mistake, amongst other things, or is agreed to in writing by all Participants.

- (s) **(Plan duration):** The Plan continues in operation until the Board decides to end it. The Board may from time to time suspend the operation of the Plan for a fixed period or indefinitely, and

may end any suspension. If the Plan is terminated or suspended for any reason, that termination or suspension must not prejudice the accrued rights of the Participants.

If a Participant and the Company (acting by the Board) agree in writing that some or all of the Securities granted to that Participant are to be cancelled on a specified date or on the occurrence of a particular event, then those Securities may be cancelled in the manner agreed between the Company and the Participant.

ANNEXURE A: NOMINATION OF AUDITOR LETTER

2 September 2026

Firebrick Pharma Limited
Level 14
333 Collins Street
Melbourne Vic 3000

NOMINATION OF AUDITOR

I, Stephen Goodall being a member of Firebrick Pharma Limited (**Company**), nominate Criterion Audit Pty Ltd (ABN 85 165 181 822) (Audit Company Rego Number 446907) in accordance with section 328B(1) of the Corporations Act 2001 (Cth) (**Act**) to fill the office of auditor of the Company.

Please distribute copies of this notice of this nomination as required by section 328B(3) of the Act.

Yours sincerely

A handwritten signature in black ink, appearing to read 'S. Goodall', with a stylized flourish at the end.

STEPHEN GOODALL

THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK

THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK

THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK

Firebrick Pharma Limited | ABN 64 157 765 896

Your proxy voting instruction must be received by **11:00am (AEDT) on Monday, 09 November 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://portal.automic.com.au/investor/home> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

12 October 2026

Upcoming Annual General Meeting of Shareholders

Dear Shareholder,

Firebrick Pharma Limited (ACN 157 765 896) (ASX: FRE) or “the **Company**”), advises that the 2026 Annual General Meeting will be held by Virtual Meeting Facility using technology through an online meeting platform powered by Automic, on Wednesday, 11 November 2026 at 11.00am (AEDT) (**Meeting**).

Notice of Meeting

The Notice of Meeting and Explanatory Statement (**Notice**) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (**Shareholders**) from the Company’s website at firebrickpharma.com/investors/ or the Company’s ASX market announcements platform at www.asx.com.au (ASX: FRE).

In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy.

Voting by Proxy

Online scan the QR code below using your smartphone 	Lodge your Proxy vote online at https://singleholding.automic.com.au/login by following the below instructions: 1. Login to the Automic website using the holding details as shown on your holding statement. 2. Click on ‘Meetings’ - ‘Vote’. To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement.
--	--

For further information on the online proxy lodgment process, or if you require a hard copy Proxy Form, please contact the Company’s Share Registry, Automic Registry Services (**Automic**), at hello@automicgroup.com.au or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Shareholder queries in relation to the Meeting

Shareholders can contact the Company Secretary with any questions prior to the meeting via email at cosec@firebrickpharma.com

Copies of all Meeting related material including the Notice and the Company’s Annual Report, are available to download from the Company’s website and the Company’s ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company’s website.

Authorised for ASX release by the Board of Firebrick Pharma Limited.